Biomoda, a cancer diagnostics company, has expanded its intellectual property (IP) portfolio with Canadian patent and trademark protection in European Union (EU).
The Canadian Intellectual Property Office issued patent 2,429,526 titled ‘Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine’.
The Canadian patent is similar to Biomoda’s US patent 6,838,248, which was issued in 2005.
The World IP Organization (WIPO), an agency of the United Nations headquartered in Geneva, has issued a certificate of registration that provides trademark protection for CyPath kits and reagents for clinical and laboratory diagnostic use in the EU.
Biomoda president John Cousins said while they work towards FDA approval and commercialization of CyPath diagnostic for lung cancer, it is critically important to make sure that the technology and the IP behind it are protected.
"We will continue to expand the geographic reach of our IP protection in order to make the CyPath assay available worldwide," Cousins said.